medigraphic.com
ISSN 1561-302X (Print)

2021, Number 4

<< Back Next >>

Rev cubana med 2021; 60 (4)

COVID-19, atherosclerosis and the inflammatory response in rheumatic disease

Iglesias D, Castro IM, Torres PL

Language: Spanish
References: 42
Page: 1-12
PDF size: 289.43 Kb.


ABSTRACT

Introduction: Coronavirus disease 2019 (Covid-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In addition to direct tissue invasion, SARS-CoV-2 can also elicit an exaggerated host immune response, often leading to a cytokine storm, significantly contributing to multi-organ dysfunction. Autoimmune diseases are characterized by a pro-inflammatory state, accelerated atherosclerosis and an increased incidence of vascular complications, which is why there is a high risk of complications in the presence of SARS-CoV-2 in these patients. Altered immune system regulation, increased metabolic demand, and procoagulant activity likely explain part of the increased risk of adverse outcomes in people with Covid-19-related atherosclerotic disease.
Objective: To update the knowledge of health personnel in the management of these diseases.
Method: We reviewed articles in PubMed, SciELO and Google Scholar with a controlled vocabulary strategy, from December 2019 to November 2020. We selected a total of 50 articles.
Findings: The high production of autoantibodies, whether secondary to rheumatic disease or due to intercurrent infection, may be involved in the development of endothelial dysfunction, the progression and rupture of the atherosclerotic plaque.
Discussion: It has been shown that these autoimmune chronic diseases are associated with high cardiovascular morbidity and mortality, so the doctor of these times must be able to recognize these patients.


REFERENCES

  1. World Health Organization WHO Director-General's opening remarks at themedia briefing on COVID-19. 2020[acceso: 25/10/2020]. Disponible en: https://www.who.int/dg/speeches/detail/whodirector-general-s-openingremarks-at-the-media-briefing-on-covid-19---11-march-2020

  2. Centers for disease control and prevention coronavirus disease. 2019[acceso:25/10/2020]. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/casesupdates/cases-in-us.html

  3. World Health Organization. Situation report. 2020[acceso: 25/10/2020].Disponible en: https://www.who.int/docs/default-source/coronaviruse/situationreports/20200403-sitrep-74-covid-19-mp.pdf?sfvrsn=4e043d03_4

  4. Ministerio de Salud Pública de Cuba. Boletín informativo sobre la COVID-19.2020[acceso: 25/10/2020]. Disponible en: https://salud.msp.gob.cu/2020/06/

  5. Ministerio de Salud Pública. Protocolo de actuación Nacional para la COVID-19versión 1.5 Infomed. 2020[acceso: 25/10/2020]. Disponible en:http://www.sld.cu/anuncio/2020/05/11/ministerio-de-salud-publica-protocolode-actuacion-nacional-para-la-covid19

  6. Jara LJ, Medina G, Saavedra MA. Autoimmune manifestations of infections.Current Opinion in Rheumatology. 2018[acceso: 13/11/2020];30(4):373-37.Disponible en:https://journals.lww.com/corheumatology/Abstract/2018/07000/Autoimmune_manifestations_of_infections.13.aspx

  7. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality dueto COVID-19 based on an analysis of data of 150 patients from Wuhan, China.Intensive Care Med. Erratum in: Intensive Care Med. 2020;46(5):846-848. DOI:https://doi.org/10.1007/s00134-020-05991-x

  8. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl JMed. 2005;352:1685-95. DOI: https://doi.org/10.1056/NEJMra043430

  9. Páramo JA, Beloqui O, Orbe J. Ciclooxigenasa-2: ¿una nueva diana terapéuticaen la aterosclerosis? Med Clin (Barc). 2006[acceso: 13/11/2020];126(20):782-86.Disponible en:http://www.sciencedirect.com/science/article/pii/S0025775306720929

  10. Bacon PA, Townend JN. Nails in the coffin: increasing evidence for the role ofrheumatic disease in the cardiovascular mortality of rheumatoid arthritis. ArthritisRheum. 2001[acceso: 13/11/2020];44:2707-10. Disponible en:https://doi.org/10.1002/1529-0131(200112)44:12<2707::AID-ART456>3.0.CO;2-M

  11. Amador-Patarroyo MJ, Rodríguez Rodríguez A, Montoya Ortíz G. How does ageat onset influence the outcome of autoimmune diseases? Autoimmune Dis.2012[acceso: 13/11/2020];2012:251730. Disponible en:http://downloads.hindawi.com/journals/ad/2012/251730.pdf

  12. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular andgenetic mechanisms of self tolerance and autoimmunity. Nature. 2005[acceso:

  13. 13/11/2020];435(7042):590-7. Disponible en:https://www.nature.com/articles/nature0372413. Zouali M. Immunological Tolerance: Mechanisms. In: eLS. John Wiley & Sons,Ltd: Chichester. 2014[acceso: 13/11/2020]. Disponible en:https://onlinelibrary.wiley.com/doi/full/10.1002/9780470015902.a0000950.pub3

  14. Goodson NJ, Solomon DH. The cardiovascular manifestations of rheumaticdiseases. Curr Opin Rheumatol. 2006;18:135-40. DOI:https://doi.org/10.1097/01.bor.0000209424.77151.66

  15. Maradit Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE.Cardiovascular death in rheumatoid arthritis: a population-based study. ArthritisRheum. 2005[acceso: 13/11/2020];52:722-32. DOI:https://doi.org/10.1002/art.20878

  16. So H, Mok CC. COVID-19 and Rheumatic Diseases: Practical Issues. JournalClinical Rheumatology and Immunology. 2020[acceso: 13/11/2020];2(1):21-4.Disponible en:https://www.worldscientific.com/doi/pdf/10.1142/S2661341720300025

  17. World Health Organization. Coronavirus disease 2019 (COVID-19) situationreports. 2020[acceso: 13/11/2020]. Disponible en:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situationreports

  18. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoidarthritis, with its comorbidity and treatment. Rheumatology (Oxford).2013[acceso: 13/11/2020];52(1):53-61. Disponible en:https://academic.oup.com/rheumatology/article/52/1/53/1830871

  19. Arleevskaya MI, Shafigullina AZ, Filina YV, Lemerle J, Renaudineau Y.Associations between viral infection history symptoms, granulocyte reactiveoxygen species activity, and active rheumatoid arthritis disease in untreatedwomen at onset: results from a longitudinal cohort study of Tatarstan women.Front Immunol. 2017[acceso: 13/11/2020];8:1725. Disponible en:https://www.frontiersin.org/articles/10.3389/fimmu.2017.01725/full

  20. De Thurah A, Stengaard-Pedersen K, Axelsen M, Fredberg U, Schougaard LMV,Hjollund NH, et al. Tele-health followup strategy for tight control of diseaseactivity in rheumatoid arthritis: results of a randomized controlled trial. ArthritisCare Res. 2018[acceso: 13/11/2020];70:353-60. Disponible en:https://onlinelibrary.wiley.com/doi/full/10.1002/acr.23280

  21. Doran M, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency ofinfection in patients with rheumatoid arthritis compared with controls: apopulation-based study. Arthritis Rheum. 2002[acceso: 20/10/2020];46(9):2287-93. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/art.10524

  22. Abudurexiti A, Adkins S, Alioto D. Taxonomy of the order Bunyavirales: Update2019. Archives of Virology. 2019;164:1949-65. DOI:https://doi.org/10.1007/s00705-019-04253-6

  23. International Commitee of taxonomy of Viruses. Taxonomy. 2020[acceso:20/10/2020]. Disponible en: https://talk.ictvonline.org/taxonomy/

  24. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020.https://doi.org/10.1038/s41586-020-2180-5

  25. Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory síndromecoronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med InfectDis. 2020:101647. DOI: https://doi.org/10.1016/j.tmaid.2020.101647

  26. Li X, Geng M, Peng Y, Men L, Lu S. Molecular immune pathogenesis anddiagnosis of COVID-19. J Pharm Anal. 2020. DOI:https://doi.org/10.1016/j.jpha.2020.03.001

  27. Ruan Q, Yang K, Wang W, Jiang L, Song J. Predictores clínicos de mortalidadpor COVID-19 basados en un análisis de datos de 150 pacientes de Wuhan, China.Med de cuidados intensivos. 2020. DOI: https://doi.org/10.1007/s00134-020-06028-z

  28. Channappanavar R, Perlman S. Infecciones patógenas por coronavirus humano:causas y consecuencias de la tormenta de citocinas y la inmunopatología. SeminImmuno Pathol. 2017;39(5):529-39. DOI: https://doi.org/10.1007/s00281-017-0629-x

  29. Siddiqi HK, Mehra MR. COVID-19 Illness in native and immunosuppressedstates: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020.DOI: https://doi.org/10.1016/j.healun.2020.03.012

  30. McDougall JA, Ferucci ED, Glover J, Fraenkel L. Telerheumatology: asystematic review. Arthritis Care Res. 2017[acceso: 20/10/2020];69(10):1546-57.Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/acr.23153

  31. Russell R. Atherosclerosis - An inflammatory disease. New Engl J Med.1999;340: 115-26. DOI: https://doi.org/10.1056/NEJM199901143400207

  32. Meek RL, Urieli-Shoval S, Benditt E. Expression of apolipoprotein serumamyloid A mRNA in human atherosclerotic lesions and cultured vascular cells:implications for serum amyloid A function. Proc Natl Acad Sci USA. 1994;91:3186-90. DOI: https://doi.org/10.1073/pnas.91.8.3186

  33. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristicsof 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ.2020[acceso: 20/10/2020];368:m1091. Disponible en:https://www.bmj.com/content/368/bmj.m1091

  34. Reyes Llerena GA, Guibert Toledano ZM, Hernández Martínez AA, OteroGonzález ZA, Bicet Dorzón E, Torres Carballeira R, et al. Las enfermedadesautoinmune-reumáticas en la epidemia por SAR-COV-2; COVID-19. Estrategias ensu manejo y actualización desde la visión de la sociedad cubana de reumatología ysu grupo nacional. Rev Cuban Reumat. 2020[acceso: 04/11/2020];22(3).Disponible en:http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/852

  35. Swiss Federal Office of Public Health. New coronavirus: documents for healthprofessionals. 2020[acceso: 20/10/2020]. Disponible en:https://www.bag.admin.ch/bag/de/home/krankheiten/ausbrueche-epidemien

  36. Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF.Rheumatic disease and COVID-19: initial data from the Covid-19. GlobalRheumatology Alliance provider registries. The Lancet. 2020[acceso:20/11/2020];2(5):E250-3. Disponible en:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30095-3/fulltext

  37. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence ofCOVID-19 in patients with rheumatic diseases? Ann Rheum Dis. 2020[acceso:20/10/2020]. Epub. Disponible en:https://ard.bmj.com/content/annrheumdis/early/2020/04/22/annrheumdis-2020-217615.full.pdf

  38. Noreña I, Fernández-Ruiz M, Aguado JM. Viral infections in the biologictherapy era. Expert Rev Anti Infect Ther. 2018[acceso: 20/10/2020];16(10):781-91. Disponible en:https://www.tandfonline.com/doi/abs/10.1080/14787210.2018.1521270

  39. D’Antiga L. Coronaviruses and immunosuppressed patients: The facts duringthe third epidemic. Liver Transpl. 2020[acceso: 20/10/2020];26(6):832-4.Disponible en:https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.25756

  40. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection:the perspectives on immune responses. Cell Death Differ. 2020[acceso:20/10/2020];27:1451-4. Disponible en: https://www.nature.com/articles/s41418-020-0530

  41. Milkus TR, Johnson SR, Fraenke L, Arasaratnam RJ, Baden LR, Bermas BL, etal. American College of Rheumatology. Guidance for the Management ofRheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 1.Arthritis & Rheumatology. 2020[acceso: 20/10/2020];72(8):1241-51. Disponibleen: https://onlinelibrary.wiley.com/doi/full/10.1002/art.41301

  42. 42 Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinicalcourse of COVID-19 in a series of patients with chronic arthritis treated withimmunosuppressive targeted therapies. Annals Rheum Dis. 2020[acceso:20/10/2020];79(5):667-8. Disponible en:https://ard.bmj.com/content/79/5/667.full




2020     |     www.medigraphic.com